23 Concerv: a prospective trial of conservative surgery for low-risk early stage cervical cancer

Objectives To prospectively evaluate the oncologic outcomes of conservative surgery in women with early stage cervical cancer. Methods From 2009–2019, a prospective, multicenter study evaluated conservative surgery in 100 eligible women from 16 sites in 9 countries. Eligibility criteria included: 1) FIGO 2009 stage IA2-IB1 cervical carcinoma; 2) squamous or adenocarcinoma histology; 3) tumor size Results Median age at surgery was 38 years (range; 23–67). Stage at diagnosis was IA2 (33%) and IB1 (67%). Histologic type included squamous cell carcinoma (48%) and adenocarcinoma (52%). Surgery included conization and LN assessment in 44/100 (44%) women and simple hysterectomy with LN assessment in 56/100 (56%) women. Minimally invasive surgery (MIS) was performed in 96/100 (96%) patients: laparoscopic in 83; robotic in 13. Positive LNs were noted in 5/100 women (5%). Residual disease in the hysterectomy specimen was diagnosed in 1/56 patients (1.8%). Median follow-up was 25 months (range 0–71). To date, recurrent disease has been diagnosed in 3 patients (3%). Conclusions Conservative surgery is oncologically safe in women with early stage, low-risk cervical carcinoma.